11 results
P
physical education students
I/C
cooperative learning methods, experimental group vs. control group
O
intrinsic motivation
P
physical education students
I/C
cooperative learning interventions, experimental group vs. control group
O
intrinsic motivation (Perceived Locus of Causality Scale)
P
children
I/C
nonpharmacological behavior guidance interventions, basic and advanced nonpharmacological techniques
O
reduction in anxiety, fear, pain, and improvement in cooperative behavior
P
patients with metastatic gastric cancer
I/C
novel immune checkpoint inhibitors (ICIs), control group
O
overall survival
P
Wilms tumor (WT) patients
I/C
surgical management, pediatric urology (PU) vs pediatric surgery (PS)
O
temporal trends in published literature, use of minimally-invasive surgery (MIS), use of nephron-sparing surgery (NSS)
P
women who underwent IVF/ICSI
I/C
thin endometrium on ovulation triggering day, thick endometrium (EMT >14 mm) and medium EMT groups (EMT 7-14 mm)
O
pregnancy outcomes (live birth rate, clinical pregnancy rate, implantation rate), hypertensive disorders of pregnancy, small-for-gestational-age infants, birthweight
P
NELM patients
I/C
TACE, TARE, TACE vs TARE
O
Overall survival, Hepatic progression-free survival, Tumor response, Complication rates
P
mothers, fathers, parents, families
I/C
co-parenting interventions, co-parenting support, couple communication, parent-child interactions, reducing co-parenting undermining, control group
O
lower depressive symptoms, improving co-parenting support, reducing co-parenting undermining, increased breastfeeding rates
P
moderate to severe depression patients
I/C
cranial electrical stimulation (CES), sham treatment
O
symptoms of depression
P
high-risk non-metastatic castrate-resistant prostate cancer (nmCRPC)
I/C
non-steroidal anti-androgens (NSAAs) and androgen deprivation therapy, androgen deprivation therapy alone
O
metastasis-free survival (MFS), overall survival (OS), prostate-specific antigen (PSA) progression-free survival (PFS), rates of grade 3 to 4 adverse events (AEs)